1286737-14-1

Basic information

• Product Name: tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxyprop-1-ynyl)picolinate
• Synonyms: tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxyprop-1-ynyl)picolinate
• CAS NO: 1286737-14-1
• Molecular Weight: 747.003
• Mol File: 1286737-14-1.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxyprop-1-ynyl)picolinate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxyprop-1-ynyl)picolinate(1286737-14-1)
• EPA Substance Registry System: tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxyprop-1-ynyl)picolinate(1286737-14-1)

Safety Data

• Hazardous Substances Data: 1286737-14-1(Hazardous Substances Data)

Upstream product

• 13610-02-1 1-phenoxy-2-propyne 
• 1235036-16-4 tert-butyl 6-(8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinolin-2(1H)-yl)-3-bromopicolinate 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 1235036-15-3 tert-butyl 3-bromo-6-chloropicolinate 
• 929000-66-8 3-bromo-6-chloropyridine-2-carboxylic acid 
• 1235034-72-6 N-(benzo[d]thiazol-2-yl)-1,2,3,4-tetrahydroisoquinoline-8-carboxamide dihydrochloride 
• 1235034-71-5 tert-butyl 8-(benzo[d]thiazol-2-ylcarbamoyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate 
• 878798-87-9 2-(tert-butoxycarbonyl)-1,2,3 ,4-tetrahydroisoquinoline-8-carboxylic acid 
• 136-95-8 2-amino-benzthiazole 

Downstream Products

• 1235036-71-1 tert-butyl 6-(8-(benzo[d]thiazol-2-yl((2-(trimethylsilyl)ethoxy)methyl)carbamoyl)-3,4-dihydroisoquinolin-2(lH)-yl)-3-(3-phenoxypropyl)picolinate 

Relevant articles and documents

Structure-guided rescaffolding of selective antagonists of BCL-X L

Because of the promise of BCL-2 antagonists in combating chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), interest in additional selective antagonists of antiapoptotic proteins has grown. Beginning with a series of selective, potent BC

HETEROCYCLIC COMPOUNDS AND METHODS OF USE

In one aspect, the present invention provides for a compound of Formula I; in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.